학술논문
Reversible Cancer Therapeutics-related Cardiac Dysfunction Complicating Intra-cardiac Thrombi
Document Type
Journal Article
Author
Arata Fukushima; Atsushi Tada; Hiroko Yamashita; Hiroyuki Iwano; Kazunori Omote; Kiwamu Kamiya; Ko Motoi; Miwa Sarashina; Rui Kamada; Sakae Takenaka; Shingo Tsujinaga; Suguru Ishizaka; Takahide Kadosaka; Takao Konishi; Takuma Sato; Takuya Koizumi; Taro Koya; Taro Temma; Tomohiro Oshino; Tomoya Sato; Toshihisa Anzai; Toshiyuki Nagai; Yasuyuki Chiba; Yoshifumi Mizuguchi
Source
Internal Medicine. 2020, 59(17):2155
Subject
Language
English
ISSN
0918-2918
1349-7235
1349-7235
Abstract
Epirubicin-based chemotherapy carries a risk of inducing heart failure, although the frequency is rare. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been widely used in patients with recurrent breast cancer as a first-line chemotherapeutic agent. Heart failure or arterial thromboembolism has been reported as a rare cardiovascular complication of bevacizumab. We herein report a breast cancer patient with reversible cancer therapeutics-related cardiac dysfunction associated with bevacizumab and epirubicin complicating intracardiac thrombi in the left atrium and left ventricle. This case underscores the importance of tailored medical planning according to the individual status in patients receiving anti-cancer therapies.